Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Breast cancer mortality correlates with tumor cell invasiveness and metastasis.
• Active H-Ras mutation induces an invasive phenotype in human breast epithelial cells.
• Ras protein membrane anchoring, crucial for its function, depends on isoprenylation via 3-hydroxy 3-methylglutaryl (HMG)-CoA reductase.

Purpose of the Study:

• To investigate the inhibitory effects of HMG-CoA reductase inhibitors (statins) on H-Ras-induced invasion in MCF10A breast epithelial cells.
• To explore the impact of statins on H-Ras membrane localization and downstream signaling pathways.
• To evaluate the potential of statins as a therapeutic strategy against breast cancer metastasis.

Main Methods:

• MCF10A cells expressing active H-Ras were treated with simvastatin and lovastatin.
• Cellular fractions were analyzed to determine the levels of isoprenylated and unprenylated H-Ras.
• The effect of statins on invasion, matrix metalloproteinase (MMP) expression, and downstream signaling was assessed, with rescue experiments using farnesyl pyrophosphate (FPP).

Main Results:

• Simvastatin and lovastatin significantly reduced membrane-bound isoprenylated H-Ras while increasing cytosolic unprenylated H-Ras.
• Statins markedly inhibited H-Ras-induced cell invasion, an effect reversible by FPP.
• Downregulation of MMP-9 and MMP-2, along with inactivation of H-Ras downstream signaling molecules, was observed.

Conclusions:

• Simvastatin and lovastatin effectively inhibit H-Ras-induced invasion, MMP expression, and signal transduction in breast epithelial cells.
• Statins interfere with H-Ras membrane anchoring, thereby suppressing its oncogenic functions.
• These findings provide a rationale for exploring statins in clinical trials to manage breast cancer metastasis.